Oral fluoropyrimidines in cancer treatment

Cancer Investigation

Volumn 18, Issue 8, 2000, Pages 747-760

  Lewis, Nancy L ^a   Meropol, Neal J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; ORZEL; OXONIC ACID; TEGAFUR; UFT;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; COMPETITIVE INHIBITION; COST BENEFIT ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0033666364     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009012207     Document Type: Article

References (83)

1. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
2. Biochemical modulation of cancer chemotherapy
3. Meta-analysis Group in Cancer: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
4. Patient preferences for oral versus intravenous palliative chemotherapy
5. 5-Fluoropyrimidines
6. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
7. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity
8. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil
9. 5-Ethynyluracil (776C85): Protection from 5-fluorouracil-induced neurotoxicity in dogs
10. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study
11. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
12. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
13. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
14. Tumor selective delivery of 5-fluorouracil by capecitabine, an oral fluoropyrimidine carbamate, in human cancer xenografts
15. Positive correlation between the efficacy of capecitabine and doxiflurimidine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities on tumors in human cancer xenografts
16. Tumor selectivity of Xeloda in colorectal cancer patients
17. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and or metastatic cancer
18. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine
19. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors
20. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
21. A multicenter phase II trial of Xeloda(TM) (capecitabine) in taxane-refractory metastatic breast cancer
22. A randomized phase II study of Xeloda (capecitabine) vs. paclitaxel in breast cancer patients failing previous anthracycline therapy
23. A randomized phase II study of Xeloda (capecitabine) vs. CMF as first-line chemotherapy of breast cancer in women aged > 55 years
24. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer
25. A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
26. A phase III trial (SO14796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer
27. Phase I study of capecitabine in combination with paclitaxel in patients with previously treated metastatic breast cancer
28. Clinical application of biochemical modulation in cancer chemotherapy: Biochemical modulation of 5-FU
29. Report on nationwide pooled data and cohort investigation in UFT phase II study
30. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958)
31. Phase I and pharmacokinetic study of oral UFT, a combination of 5-fluorouracil prodrug tegafur and uracil
32. Phase I clinical trials and pharmacokinetics of uracil-ftorafur combination (UFT) and leucovorin (LV) in patients with advanced colorectal cancer
33. Phase I trials of uraciltegafur (UFT) using 5- and 28-day administration schedules: Demonstration of schedule-dependent toxicities
34. Phase I circadian dosing of daily oral uracil (U) plus 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) with leucovorin (LV)
35. Phase I study of UFT plus leucovorin in advanced colorectal cancer: A double modulation proposal
36. Phase I trial of uraciltegafur (UFT) plus oral leucovorin: 14 day schedule
37. A fixed-ratio combination of uracil and ftorafur (UFT) with low-dose leucovorin. An active oral regimen for advanced colorectal cancer
38. A phase I and pharmacokinetic study of oral uracil, ftorafur and leucovorin in patients with advanced cancer
39. Phase I trial of uraciltegafur (UFT) plus oral leucovorin: 28 Day schedule
40. 1-(2'-tetrahydrofuryl)-5-fluorouracil
41. Phase II trial of UFT in advanced colorectal and gastric cancer
42. Tegafur UFT in advanced colorectal cancer; a phase II study
43. Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study
44. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of colorectal cancer
45. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer
46. Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients
47. Randomized comparative study of ORZEL (oral uracil-tegafur (UFT) plus leucovorin (LV)) vs parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer
48. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer
49. A phase II trial. Oral UFT and leucovorin in patients with advanced gastric carcinoma
50. A cooperative randomized study of tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer
51. Randomized controlled trial of MMC + UFT and MMC + 5-FU therapy in advanced gastric cancer
52. Combination chemotherapy with tegafur-uracil (UFT) and cisplatin (CDDP) for advanced gastric cancer
53. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A Phase II Study of the ONCOPAZ Cooperative Group
54. Multicentre randomized study of adjuvant chemotherapy with mitomycin C and tegafururacil in gastric cancer
55. Clinical trials on UFT in the treatment of head and neck cancer
56. Neoadjuvant therapy with cisplatin/fluorouracil versus cisplatin/UFT in locally advanced squamous cell head and neck cancer
57. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil versus cisplatin and ftorafur-uracil (UFT) in advanced squamous head and neck cancer
58. Phase II trial of UFT activity in pretreated breast cancer patients
59. A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at the Phillipines General Hospital
60. Oral UFT/LV in combination with paclitaxel in the second-line treatment of patients with metastatic breast cancer: Results of a phaseI/II trial
61. UFT in combination as adjuvant therapy in breast cancer
62. A phase II trial. UFT plus cisplatin in advanced non-small cell lung cancer: Interim analysis of 67 patients
63. A randomized controlled post-operative adjuvant chemotherapy trial of MMC + tegafur and MMC + UFT for adenocarcinoma of the lung - First study
64. Adjuvant chemotherapy after complete resection in non-small cell lung cancer
65. 5-Ethynyluracil (776C86): Modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma
66. Pharmacokinetics, oral bioavailability, and safety study of fluorouracil in patients treated with 776C 85, an inactivator of DPD
67. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer
68. A phase I and pharmacologic (PK/PD) study of weekly oral fluorouracil (Fura) given with eniluracil (GW 776C85) and leucovorin in patients with solid tumors
69. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
70. Phase I and pharmacologic study of oral 5FU on a chronic 28 day schedule in combination with the DPD inactivator 776C85
71. A phase III trial of a seven-day regimen of oral 776C85 plus a 5-day regimen of oral 5fluorouracil (5-FU) in untreated patients with metastatic colorectal cancer: A NCCTG study
72. A phase II open-label study to evaluate a 28-day regimen of oral 5-fluorouracil (5-FU) plus 776C85 for the treatment of patients with previously untreated metastatic colorectal cancer
73. Eniluracil/5-FU in anthracycline and taxane-refractory breast cancer
74. 2 for 2 daily) as first line chemotherapy in patients with advanced breast cancer: A phase II study
75. A multicenter phase II trial of oral eniluracil plus 5-FU in patients with inoperable hepatocellular carcinoma
76. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats
77. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S an oral 5-fluorouracil prodrug in a colorectal tumor model
78. Phase I clinical and pharmacokinetic study of S an oral 5-fluorouracil (5-FU)-based antineoplastic agent
79. Phase I and pharmaacokinetic (PK) study of the novel oral fluoropyrimidine, S-1
80. Late phase II study of novel oral fluoropyrimidine anti-cancer drug S-1 (1M tegafur-0.4M gimestat otastat potassium) in advanced gastric cancer patients
81. Late phase II study of S a novel oral fluoropyrimidine derivative in patients with advanced gastric cancer
82. Late phase II study of Sin patients with advanced colorectal cancer in Japan